JAZZ – jazz pharmaceuticals plc - ordinary shares (US:NASDAQ)
Stock Stats
News
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium [Yahoo! Fina
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
A Look at Jazz Pharmaceuticals's Valuation After Breakthrough Phase 3 Ziihera Trial Results [Yahoo! Finance]
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
Form 4 Jazz Pharmaceuticals For: Dec 02 Filed by: O'Keefe Kenneth W
Form 144 Jazz Pharmaceuticals Filed by: O'Keefe Kenneth W
Form 4 Jazz Pharmaceuticals For: Nov 26 Filed by: COZADD BRUCE C
Form 144 Jazz Pharmaceuticals Filed by: COZADD BRUCE C
Form 4 Jazz Pharmaceuticals For: Nov 20 Filed by: McSharry Heather Ann
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.